Engineering a delivery device and development of a novel formulation for chronic obstructive pulmonary disease and cystic fibrosis

设计一种输送装置并开发一种治疗慢性阻塞性肺病和囊性纤维化的新型制剂

• 批准号: LP0776892
• 负责人: Prof Paul Young
• 金额: $ 23.32万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-04-24 至 2011-11-28
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP0776892
• 关键词: Engineering; delivery; device; development; novel

This project will position Australia to become one of the world leaders in the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and other chronic respiratory diseases. The financial burdens of COPD and CF come to at least $900 million a year in Australia alone. These diseases have significant impact on patients and the health system through regular clinical visits, hospitalisation and employment downtime. The global market for the treatment of COPD is currently more than $8 billion and is expected to increase substantially. The positioning of an Australian pharmaceutical company at the forefront of COPD/CF treatment will have significant national benefits for patients, the health system, and research infrastructure in the field.

该项目将使澳大利亚成为治疗慢性阻塞性肺疾病(COPD)、囊性纤维化(CF)和其他慢性呼吸道疾病的世界领先者之一。仅在澳大利亚，慢性阻塞性肺病和慢性阻塞性肺病每年造成的经济负担就至少达到9亿美元。这些疾病通过定期临床就诊、住院和停工时间对患者和卫生系统产生重大影响。治疗慢性阻塞性肺疾病的全球市场目前超过80亿美元，预计将大幅增加。将一家澳大利亚制药公司定位在慢性阻塞性肺疾病/慢性阻塞性肺疾病治疗的前沿，将为患者、卫生系统和该领域的研究基础设施带来重大的国家利益。